NCT05677542

Secukinumab (Cosentyx®) Effectiveness in Axial Spondyloarthritis and Psoriatic Arthritis Patients Using Artificial Intelligence (SpAINET): Spanish Multicenter, Retrospective, Real World Evidence Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 758 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This was a multicenter, retrospective, and non-interventional study using secondary data captured in the Electronic Health Records (EHRs). The extraction of the data captured in the EHRs was performed with EHRead® by SAVANA, an innovating data-driven system based on Natural Language Processing (NLP) and big data analytics. Data was extracted and analyzed at Index Date, Follow Up, or as specified for each variable.

Conditions

• Axial Spondyloarthritis
• Psoriatic Arthritis

Interventions

Type	Name	Description
DRUG	secukinumab	all patients who received secukinumab

Timeline

• Start date: 2021-06-02
• Primary completion: 2021-12-31
• Completion: 2021-12-31
• First posted: 2023-01-10
• Last updated: 2023-01-10

Locations

3 sites across 1 country: Spain